Dompé

Dompé is a private, family-owned biopharmaceutical company with more than 130 years of independent history, focused on redefining treatments for ophthalmic, neurological, and pain-related conditions through breakthrough science.

As the first company to unlock the therapeutic potential of nerve growth factor (NGF), Dompé is advancing first-in-class, disease-modifying therapies that target the underlying causes of nerve damage rather than symptoms alone. Building on Nobel Prize-winning science, our work has already led to the approval of the first topical biologic in ophthalmology for a rare neurotrophic eye disease, and continues to expand into high-unmet-need areas across eye, brain, and pain indications.

Our research and development model combines scientific rigor with agility. Our curiosity-driven R&D team follows the science where it leads - developing innovative biologics, advancing multiple clinical programs, and exploring new delivery platforms - to address complex and hard-to-treat diseases.

Independence is central to who we are. It enables long-term thinking, sustained investment in innovation, and the ability to integrate research, manufacturing, and commercialization with the discipline of an established pharmaceutical company and the speed of a biotech.

Beyond science, Dompé is deeply committed to patients, access to care, and the next generation of scientific leaders—through patient support programs and long-standing investments in education and talent development.

Our mission is clear: to bring the full potential of NGF and other breakthrough molecules to patients, and in doing so, transform how diseases of the nervous system are treated.